Disease · HP_0001510
Growth delay
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Growth delay. Diseases, record HP_0001510. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001510
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Growth delay
- Open Targets ID
- HP_0001510
- Other names
- Delayed growth, Growth deficiency, Growth failure, Growth retardation, Poor growth, Retarded growth
- Highest stage of its drugs
- Approval, for 3 of its 12 drugs, from DailyMed and TTD
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SOMATROPIN | CHEMBL1201621 | Protein | Approval | DailyMed | 27 | 22 | 21 | Drugs and targets |
| MECASERMIN | CHEMBL1201716 | Protein | Approval | DailyMed and TTD | 6 | 4 | 3 | Drugs and targets |
| LONAPEGSOMATROPIN | CHEMBL4298185 | Protein | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| ALBUSOMATROPIN | CHEMBL4298125 | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets | |
| SOMAPACITAN | CHEMBL3707290 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
| LETROZOLE | CHEMBL1444 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SEBELIPASE ALFA | CHEMBL3039537 | Enzyme | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TESTOSTERONE | CHEMBL386630 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RINFABATE | CHEMBL2108047 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| OXANDROLONE | CHEMBL1200436 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets4
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| GHR | Growth hormone receptor | 4 | Growth hormone receptor agonist | Approval | https://conductscience.org/library/genes/2690 | Drugs and targets |
| AR | Androgen receptor | 2 | Androgen Receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/1588 | Drugs and targets |
| IGF1R | Insulin-like growth factor 1 receptor | 1 | Insulin-like growth factor I receptor agonist | Approval | https://conductscience.org/library/genes/3480 | Drugs and targets |
Trials29
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00125164 | Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency | Phase 3 | 137 | 2010-04-30 | Growth Disorders, Insulin-Like Growth Factor-1 Deficiency | MECASERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT02879747 | Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children | Phase 2/3 | 99 | 2019-04-30 | Short Stature | SOMATROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT00163189 | Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm | Phase 3 | 98 | 2015-06-25 | Growth Hormone Deficiency | SOMATROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT00174252 | Study Aimed At Improving Height With Genotonorm In Children Born Little And/Or Light With Growth Retardation At The Age | Phase 3 | 57 | 2010-06-04 | Fetal Growth Retardation | SOMATROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT00163215 | Growth Retardation In Children With Special Pathological Conditions Or Disease | Phase 3 | 46 | 2012-12-19 | Endocrine System Diseases | SOMATROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT00174291 | Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy | Phase 3 | 21 | 2012-12-04 | Endocrine System Diseases | SOMATROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT01371825 | Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency | Phase 2/3 | 9 | 2016-04-18 | Lysosomal Acid Lipase Deficiency, Wolman Disease | SEBELIPASE ALFA | Its record names the disease | ClinicalTrials.gov |
| NCT00490100 | Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1 | Phase 1/2 | 6 | 2015-07-03 | Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID), Growth Hormone Resistence | MECASERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT01543867 | Safety and Efficacy of Long-term Somatropin Treatment in Children | 5,442 | Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem, Small for Gestational Age, Genetic Disorder, Turner Syndrome, Growth Disorder, Idiopathic Short Stature | SOMATROPIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT00747604 | IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex | 1,378 | Primary Insulin-like Growth Factor-1 Deficiency | MECASERMIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 29
See all 29 trialsComparisons in its trials1
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial |
|---|---|---|---|---|
| Somatropin (With Previous Somatropin Exposure) vs Somatropin (Without Previous Somatropin Exposure): serious adverse events | 6 of 11 | 2 of 10 | 21 | NCT00174291 |
Source Trial comparisons
Papers from its trials18
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001510
GET https://conductscience.org/api/diseases/v1/HP_0001510/trials?page=2